background class drug rapid develop therapeutic treat emerge infect challenge timeline need identify compound desire efficacy safety pharmacokinet profil full human monoclonal antibody mab provide attract method overcome mani hurdle rapidly product disease method studi deploy platform genre test develop air ebolaviru obtain specify antiebola virus erov immune velocimmun mouse use immunoglobulin variable region humor response result antibody clone iso select best neutral trigger fcÎ³rica bind studi negativestain electron microscopy reveal bind nonoverlap editor include potent new protect editor target antibodybas treatment combine single dose cocktail protect inhuman prima hp disease even symptom appear concur provide complementary meghan action incorpor novel specify demons highlevel postexposur protect lethal undergo test normal health volume prepare potent future ebola spider 